Michal Bartos

Pharma veteran

📍 Basel, Basel-Town, Switzerland🔄 Updated September 2026💼 3 investments📅 11 years investing🗓 Last invested Nov 2019𝕏 @upgrade_to_unlock
VC🌍 Switzerland
3
Total investments
1
Early stage
0
Mid stage
1
Late stage
11y
Years active

Portfolio

2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Nov 2019
SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a proprietary technology designed to improve on the efficacy of CAR T therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group.
Lead Investor, Board Member and Acting CFO
Jun 2018
Resistell proposes an alternative to culture based antibiogram, the current gold standard in antibiotic susceptibility testing. Our offering is a diagnostic device. The rapid AST method is based on the detection of movement caused by living bacterial cells. Because the test is growth independent rapid AST, we reduce the time taken to get a result from days to minutes. Resistell provides information on which antibiotic should be used to treat the patient, and the concentration at which it should be administered.
Experience · 6 entries
All (6)
Investments (3)
Founder (2)
Board (2)
2019
Board Member
Nov 2019
SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a proprietary technology designed to improve on the efficacy of CAR T therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group.
2018
Lead Investor, Board Member and Acting CFO
Jun 2018
Resistell proposes an alternative to culture based antibiogram, the current gold standard in antibiotic susceptibility testing. Our offering is a diagnostic device. The rapid AST method is based on the detection of movement caused by living bacterial cells. Because the test is growth independent rapid AST, we reduce the time taken to get a result from days to minutes. Resistell provides information on which antibiotic should be used to treat the patient, and the concentration at which it should be administered.
2015
ARTO AG
Founder and CEO
Jan 2015
.
Angel Investor and Start-up Coach
Jan 2015
Founder and CEO
Jan 2015
In the area of healthcare, ARTO develops and implements together with its clients tailor-made solutions for a wide range of strategic and operational topics. Youll find a few showcase examples of projects at linkedin.com/in/artoagbasel . Please visit also my personal LinkedIn profile at linkedin.com/in/michalbartos .
Show all 6 entries ↓
Investment activity
2015–2019 · 3 investments
201512018120191
Recent (last 2 years)Earlier